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Abstract  
INTRODUCTION: Multiple epidemiological studies have shown that low testosterone levels are 
associated with and predict the future development of T2DM. 
AIM: The aim of study was to show the influence of testosterone replacement therapy on 
anthropometric characteristics, glycosylated hemoglobinlevel level, blood pressure and 
dyslipidemia in patients with T2DM and Androgen deficiency. 
MATERIALS AND METHODS:  From 125 male patients with T2DM were randomized 85 subjects 
with age 49.8 ± 6.74 and BMI from 35.83 ± 3.65 kg/m
2
 in placebo-controlled study. We divided 
patients into two groups: 1) Treatment group, where was used testosterone replacement therapy. 2) 
Placebo group, where was used placebo. In both groups was added Life style modification, but 
Antidiabetic therapy was unchanged. 
RESULTS: After six months of treatment we repeated the diagnostic assessments: lipid profile was 
improved in both groups but in group I it was statistically significant. Free testosterone level 
increased in all groups but in group I it was statistically significant. HbA1c decreased in both group 
but in group I we had the best result. Blood pressure was reduced in both groups, results were 
similar. 
CONCLUSION: Our study demonstrated that it is possible to regulate blood pressure, lipid profile, 
HbA1c, BMI - by raising testosterone in diabetic men with androgen deficiency. 
 
 
 
 
Introduction 
 
Over the past few decades, obesity and type 
2 diabetes mellitus (T2DM) has become a global 
health challenge. The number of people with obesity 
and T2DM has dramatically increased in the whole 
world, and Georgia is not the exception [1, 2]. Men 
with obesity, metabolic syndrome (MS), and T2DM 
have low total, free testosterone and sex hormone–
binding globulin (SHBG) levels [3]. Conversely, the 
presence of low testosterone and/or SHBG predicts 
the development of metabolic syndrome and type 2 
diabetes. Visceral adiposity, presented in men with 
low testosterone, metabolic syndrome, and/or T2DM, 
acts through pro-inflammatory factors. These 
inflammatory markers contribute to vascular 
endothelial dysfunction with adverse sequel such as 
increased cardiovascular disease (CVD) risk and 
erectile dysfunction (ED). Furthermore, studies show 
multidirectional impact of low testosterone level with 
obesity and MS and its negative effect on ED and 
CVD risk in men with T2DM [4].  
Androgens play an important role not only in 
sex differentiation and development, but also in 
regulating the metabolism of glucose, protein, lipid 
and some inflammatory factors, all of which might 
have a great influence on insulin sensitivity. It is well 
known that reduced level of total testosterone (TT) in 
middle aged or in old men may contribute to 
abdominal obesity, increased insulin resistance, and 
diabetes mellitus. At least 6 large prospective clinical 
trials have suggested that reduction of TT predicted 
the increasing incidence of type 2 diabetes [5-6]. Low 
concentrations of endogenous androgens have been 
linked with insulin resistance, which is an important 
upstream driver for metabolic abnormalities [7-8]. 
Moreover, results from the Massachusetts Male Aging 
Study suggest, that low concentration of testosterone 
might play a role in the development T2DM [9-10]. 
Studies in laboratory animals support the hypothesis 
that diabetes has s detrimental effects on testicular 
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function; reduction in both Leyding cell number and 
testosterone secretion have been reported [11]. 
As it was previously shown the patients with 
type 2 diabetes have a frequent occurrence of hypo-
gonadotrophic hypogonadism, as reflected in low 
plasma concentrations of testosterone and 
inappropriately low luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) [12]. In addition, 
the lack of testosterone would also potentially promote 
further weight gain and loss of skeletal muscle and 
would thus promote insulin resistance [13-14]. 
In the European Male Aging Study database 
of 3,369 men between the ages of 40 and 79 years, 
three sexual symptoms (poor morning erections, low 
sexual desire, and ED) had a syndrome relationship 
with decreased testosterone levels [15]. Moreover, in 
the European Male Aging Study, low serum 
testosterone was more frequent in men with 
comorbidities such as obesity, metabolic syndrome, 
and type 2 diabetes. In studies from diabetes clinics, 
total, bioavailable, and free testosterone levels were 
low in men with type 2 diabetes [16-17]. When 
comparing testosterone levels in men with and without 
ED and type 2 diabetes, these investigators found 
significantly lower serum bioavailable testosterone (P 
= 0.006) and free testosterone (P = 0.027) in men with 
ED, but there was no significant difference in total 
testosterone levels. The lower the serum testosterone 
appears, the greater the severity of ED is suggested 
[16]. Corona et al. [18] evaluated 1,200 men with ED 
and reported that 16% had type 2 diabetes. Serum 
total testosterone levels were below the reference 
range (300 ng/dL or, 10.4 nmol/L) in 24.5% of men 
with diabetes versus 12.6% of non-diabetic subjects 
(P = 0.0001) after adjustment for age and BMI. In 
addition, hypogonadism in men with type 2 diabetes 
was associated with decreased sexual desire, more 
symptoms of depression, and lower luteinizing 
hormone levels. Multiple epidemiological studies have 
shown that low testosterone levels are associated with 
and predict the future development of T2D and the 
metabolic syndrome [19]. 
A meta-analysis by Ding et al. [20] analyzed 
20 cross-sectional where total testosterone levels 
were consistently lower in diabetic men compared 
with non-diabetic controls in all individual studies. 
These findings were confirmed by a more recent 
meta-analysis of 28 cross-sectional studies including 
1,822 men with diabetes and 10,009 non-diabetic 
controls by Corona et al. [21]. 
However, a cross sectional study from the 
Third National Health and Nutrition Examination 
Survey (NHANES) group including 1,413 adult men, 
101 of which had diabetes, showed that men in the 
lowest fertile of calculated free testosterone, adjusted 
for age, ethnicity, and adiposity, were more likely to 
have prevalent diabetes [22]. In addition, a recent 
cross sectional analysis of 1292 men from the Norfolk 
population found that the 156 men with a hemoglobin 
A1c (HbA1c) of at least 6.5% or self-reported diabetes 
had, compared with men with an HbA1c no greater 
than 5%, a 2.4 nmol/liter lower circulating total and a 
30 pmol/liter lower free testosterone level, respectively 
(P 0.001) [23]. Studies from Australia [24], the 
United Kingdom [25], and the United States [26] 
consistently showed that 30–50% of aging, obese 
men with diabetes, in the absence of known testicular 
or pituitary pathology, have low total or free 
testosterone, at least relative to reference ranges 
based on healthy young men [24-26].  
The aim of study was to show the influence of 
testosterone replacement therapy on anthropometric 
characteristics, glycosylated hemoglobin (HbA1c) 
level, arterial blood pressure and dyslipidemia in 
patients with T2DM and Androgen deficiency. 
 
 
Materials and Methods 
 
One hundred and twenty five male patients 
with T2DM were screened from the year 2010 till the 
end of the year 2013, at “National Institute of 
Endocrinology” (Tbilisi, Georgia). The study was 
approved by the Ethics Committee of this Institute. 
Written informed consent was obtained from all 
participants. Every possible side effect of the 
treatment was written in the inform consent. All 
patients had to meet inclusion criteria: T2DM; Body 
mass index (BMI) 27.0 – 48.0 kg/m
2
; patient age 
range 30-65 years; positive screening questionnaire 
for androgen deficiency in males (Adapted from 
Morley JE, et al.), low free testosterone level (free 
testosterone and not total testosterone measurements 
was preferred by “National Institute of 
Endocrinology”).  
Patients with following criteria were excluded 
from the study:  diabetes mellitus type 1; 
hyperprolactinemia; BMI < 27 kg/m
2
 and > 48 kg/m
2
; 
kidney and liver active disease; adenoma of prostate 
II-III degree; secondary hypogonadism, treated by 
testosterone or testosterone stimulation therapy 3 
month before screening; treatment with anti-obesity 
drugs within 3 months prior to informed consent; 
uncontrolled hyperglycemia with glucose level >240 
mg/dl (> 13.3 mmol/L); any previous (or planned 
within next 12 months) bariatric surgery (open or 
laparoscopic) or intervention (gastric sleeve); current 
treatment with systemic corticosteroids at the time of 
informed consent or pre-planned initiation of such 
therapy (Note: inhaled use of steroids (e.g. for 
asthma/COPD) is no exclusion criterion, as this does 
not cause systemic steroid action); congestive heart 
failure (NYHA III or IV); acute or chronic metabolic 
acidosis (present condition in patient history); 
hereditary galactose intolerance; alcohol or drug 
abuse within the 3 months prior to informed consent 
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that would interfere with trial participation; acute 
coronary syndrome ≤ 6 weeks prior to informed 
consent; stroke or transitory ischemic attack (TIA) ≤ 3 
months prior to screening; change in dose of thyroid 
hormones and dyslipidemia therapy within 6 weeks 
before screening; coumarin therapy within 6 months 
prior informed consent.  
The following analyses were conducted at the 
screening visit: 1) anthropometric study: height and 
weight were evaluated in all subjects. BMI was 
calculated as weight (kg) divided by square of height 
(m²) and was expressed in kg/m². Waist 
circumference was measured midway between the 
iliac crest and the lower margin of the 12
th
 rib. For 
measurement of supine blood pressure, subjects were 
in a supine or semi-recumbent position for minimum 5 
minutes. After that blood pressure was measured 
twice with minimum 2 minute interval. The difference 
was not > 2 mmHg mark on the manometer. The final 
result was recorded.  Blood pressure was measured 
with automatic manometer - Microlife BP100.  All 
anthropometric measurements were done by 
investigator - Sh. J. 2) Venous blood samples were 
obtained from 9:00 to 11:00 a.m. after 10-12-h fast 
and stored at 4ºC.  HbA1c, liver function tests, lipid 
profile were evaluated by liquicolor HUMAN test. All 
hormones: free testosterone, leptin, prostate specific 
antigen (PSA), thyroid stimulation hormone (TSH), 
follicle stimulation hormone (FSH), luteinizing 
hormone (LH) were performed by the fully automated 
enzyme-linked immunosorbent test (ELISA) analyzer 
Elisys Uno (HUMAN Diagnostics, Wiesbaden, 
Germany). 3) All patients filled the validation of a 
screening questionnaire for androgen deficiency in 
males (Adapted from Morley JE, et al.). 4) 
Ultrasonography of the abdomen and prostate were 
performed with a Siemens Acuson Antara. 5) 12 lead 
Electrocardiography (ECG) was performed with a 
Biocare ECG-3030. 
A total of 85 subjects with age range 49.8 ± 
6.74 years and BMI from 35.83 ± 3.65 kg/m
2
 were 
randomized in placebo-controlled study. According to 
the laboratory and clinical condition we divided 
patients into two groups. 1) Treatment group (42 
patients) and 2) placebo group (43 patients). 
Antidiabetic therapy was not changed in both groups. 
Lifestyle modification was the same in both groups: 
1600-2000 calorie diet (30% fat, 30% protein and 40% 
carbohydrates) taken 4-5 times per day. No additional 
food intake was allowed. Walking - 150 min/week was 
recommended for all patients.  The first group 
received testosterone replacement therapy (TRT) - 
testosterone undecanoate 1000 mg/4ml 
intramuscularly once in three month (Nebido - depot 
preparation of testosterone undecanoate used every 
10-14 week, Jenafarm GmbH & CO.KG). The second 
group received placebo. 
Diagnostic assessment (weight, waist 
circumference, blood pressure, HbA1c, lipid profile, 
liver function tests, free testosterone, leptin, PSA, 
TSH, FSH, LH) was done to all patients at baseline 
and after 6 month treatment period. all patients were 
given home blood glucose and blood pressure 
monitoring diaries and were informed to do the 
monitoring at least 2 times per week. If their fasting 
blood glucose level was >200 or <70 mg/dl or DBP 
(Diastolic blood pressure) >160 or SBP (systolic blood 
pressure) >90 mmHg, they had to contact their study 
doctor. 
Shapiro-Wilk test was used to determine 
normality of data distribution. The results were 
presented as mean ± standard deviation (SD) and 
95% confidence interval (CI 95%) for normally 
distributed data. Not normally distributed data were 
displayed as median with range (min – max values). 
Differences between the study group and control 
group patients were measured using independent 
samples T-test for normally distributed data and 
Mann-Whitney U test for not normally distributed 
variables. Pearson (r) correlation tests were used to 
determine the relationship between study parameters, 
depending on variable distribution. P-value < 0.05 was 
considered statistically significant. Statistical analysis 
was performed using the SPSS 15.0 software 
package (SPSS, Inc., Chicago, IL). 
 
 
Results 
 
Average level of BMI was 35.83 kg/m2. In all 
investigated patients increased level of leptin and 
decreased level of free testosterone was observed at 
baseline and was in average 22.31 ng/ml (n. 0.2-5.0 
ng/ml)  and 3.85 ng/dl (n. 5.8-36 ng/dl) relatively. The 
average level of glycosylated hemoglobin (HbA1c) 
was 8.35%.  Abnormal lipid profile was observed in 
each patient.  59 patients had arterial hypertension 
(Table 1).  
Table 1:  Descriptive characteristics form randomized patients.  
Parameter Mean ± SD (  =85) 
Age (year) 49.8 ± 6.74 
BMI (kg/m
2)
 35.83 ± 3.65 
WC (sm) 119.7 ± 15.98 
SBP (mmHg) 130.11 ± 12.61 
DBP (mmHg) 86.13 ± 10.33 
F.test. (ng/dl) 3.82 ± 3.0.68 
HbA1c (%) 8.35 ± 0.97 
Leptin (ng/ml) 22.31 ± 8.97 
Chol (mg/dl) 209.2 ± 15.05 
TG (mg/dl) 183.88 ± 12.5 
HDL (mg/dl) 54.74 ± 4.75 
LDL (mg/dl) 101.25 ± 9.62 
DM 85 ± 0 
AH 59 ± 0 
Data are expressed as mean ± SD. BMI: body mass index, WC: waist circumference, 
SBP: systolic blood pressure, DBP: diastolic blood pressure, F. test: Free testosterone, 
HbA1c: Glycosylated hemoglobin, Chol: Cholesterone HDL: high-density lipoprotein 
cholesterol, LDL: low-density lipoprotein cholesterol, TG: triglyceride, TC: total cholesterol, 
DM: Diabetes Mellitus and AH: arterial hypertension. 
 
Free testosterone level was inversely 
correlated with the degree of obesity (BMI) (Fig. 1) (r-
0.10). There was no statistically significant correlation 
between free testosterone and waist circumference (r-
0.56). 
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Figure 1: Correlation between BMI and free testosterone. 
 
The patients were randomized in one side-
blinded two groups 1) first group consisted of 42 
patients, 2) second group consisted of 43. In first 
group existing anti-diabetic therapy remained 
unchanged, but was added lifestyle modification and 
testosterone replacement therapy (TRT). The second 
group received placebo.  
Table 2: Descriptive characteristics: Before and after 
Treatment in both group.  
  
Group I: before 
treatment 
average results 
(n43) 
Group II: before 
treatment 
average results 
(n42) 
Group I: after 
treatment 
average 
results (n43) 
Group II: after 
treatment 
average results 
(n42) 
P value 
BMI (kg/m
2)
 35.65±3.78 36.60±3.57 29.68±3.10 31.88±3.16 0.046 
F.test.(ng/dl) 3.85±0.57 3.8±0.78 12.06±3.57 6.64±1.07 0.047 
HbA1c (%) 8.26±0.87 8.43±1.07 7.46±0.76 7.93±0.71 0.051 
Leptin (ng/ml) 21.71±8.13 23.19±9.73 11.64±4.27 13.93±4.00 0.052 
Chol (mg/dl) 211.17±15.68 207.28±14.35 194.64±7.62 198.02±6.77 0.05 
TG (mg/dl) 185.6±11.66 182.21±13.20 178.31±9.4 180.23±10.25 0.047 
HDL (mg/dl) 55.5±4.96 54±4.48 71.11±4.42 68.44±5.80 0.048 
LDL (mg/dl) 102.95±9.60 99.58±9.46 95.62±9.72 96.3±10.27 0.049 
Data are expressed as mean ± SD. BMI: body mass index, F. test: Free testosterone, 
HbA1c: Glycosylated hemoglobin, Chol: Cholesterol HDL: high-density lipoprotein 
cholesterol, LDL: low-density lipoprotein cholesterol, TG: triglyceride, TC: total cholesterol. 
 
After six month of treatment in both groups 
positive results were shown according to lipid profile: 
total cholesterol, triglyceride and LDL levels 
decreased, and HDL increased in both groups but 
statistically significant results were shown in the first 
group (Table 2, Fig. 2). Free testosterone level 
increased in both groups but statistically significant 
results was shown only in the first group (P = 0.047) 
(Table 2, Fig. 3). HbA1c decreased in both groups but 
in the first group results were better (P = 0.051) (Table 
2, Fig. 4). BMI decreased in both groups but more 
reduction was seen in the first group (P = 0.046) 
(Table 2, Fig. 5). Leptin level after treatment was 
approximately same in both groups, but relatively best 
results were achieved in the first group (P = 0.052) 
(Table 2, Fig. 6). Blood pressure reduction was the 
same in both groups (Fig. 7). 
 
Figure 2: Descriptive characteristics: before and after treatment. 
 
 
Discussion 
 
Serum testosterone, glycosylated hemoglobin 
(HbA1c), high-density lipoprotein cholesterol, 
triglyceride concentrations, BMI, and blood pressure 
improved in both groups after 6 month of the 
treatment.  Our study showed that diabetic men have 
lower testosterone level then non-diabetic.  
 
Figure 3: Descriptive characteristics: Free testosterone before and 
after treatment in both groups. 
 
A meta-analysis by Ding et al. [20], who 
analyzed 20 cross-sectional studies with a total of 850 
men with diabetes and 2000 non-diabetic controls, 
also showed that total testosterone levels were 
consistently lower in diabetic men compared with non-
diabetic controls in all individual studies, with a mean 
pooled difference of 2.66 nmol/liter [95% confidence 
interval (CI), 3.45 to 1.86]. Our findings were also 
confirmed by a more recent meta-analysis of 28 
cross-sectional studies including 1,822 men with 
diabetes and 10,009 non-diabetic controls by Corona 
et al. [21]; total testosterone was lower in men with 
diabetes compared with controls [mean difference, 
2.99 nmol/liter (95% CI, 3.59 to 2.40)], and diabetes 
remained associated with lower total testosterone 
levels independent of age and BMI (adjusted r = 
0.568; P = 0.0001) (6). Neither Ding et al. [20] nor 
Corona et al. [21] analyzed the association of free 
testosterone levels with diabetes, due to the lack of 
reliable data. 
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Figure 4: Descriptive characteristics: Glycosylated haemoglobin 
before treatment and after treatment in both groups. 
 
We have shown that testosterone 
replacement therapy improves insulin resistance in 
hypogonadal men with diabetes. Testosterone therapy 
reduced the HbA1c, indicating an improved glycemic 
control. This study demonstrates that intramuscular 
testosterone replacement therapy (TRT) in 
hypogonadal men with type 2 diabetes improves 
HbA1c, the central biochemical defect associated with 
these conditions. Small-scale studies of testosterone 
treatment in men with metabolic syndrome or type 2 
diabetes and marginal low or normal testosterone 
levels showed improvement in glycemic control. More 
studies have to be conducted to confirm our findings.   
 
Figure 5: Descriptive characteristics: BMI before and after treatment 
in both groups. 
 
The low testosterone levels might have 
induced an increase in visceral obesity and severity of 
cardiovascular risk factors in T2DM. Increased age is 
one of the strongest predictors for coronary artery 
disease [29]. The studies have shown that 
hypogonadism is associated with dyslipidemia, there 
are only limited data supporting the effect of 
testosterone on lipids. Two studies reported a small 
rise in HDL cholesterol but no effect on TC or LDL 
cholesterol in hypogonadal men [27]. Our results 
showed that after TRT, total cholesterol, LDL-C, 
triglyceride had reduced and HDL increased by 16.53 
mg/dl, 7.33 mg/dl, 7.29 mg/dl and 15.61 mg/dl 
respectively, which are consistent with other TRT 
trials′ results [28]. It is not yet fully understood whether 
hypoandrogenaemia causes the metabolic syndrome 
and T2DM or vice versa. Hypoandrogenaemia often 
precedes adult male obesity indicating that low 
androgen levels may be the precursor of insulin 
resistance, the metabolic syndrome and finally T2DM 
in obese men. A prospective study of 11 years 
duration revealed that low plasma testosterone levels 
independently predicts the development of the 
metabolic syndrome and T2DM and contribute to their 
pathogenesis [30]. 
 
Figure 6: Descriptive characteristics: Leptin (ng/ml) level before and 
after treatment in both groups. 
 
Lower levels of testosterone in men are 
associated with high blood pressure. Our study 
demonstrated a favorable effect of testosterone 
treatment on blood pressure in abdominally obese 
men. Other studies by Marin P et al and Yassin AA et 
al investigating the effects of testosterone treatment of 
men with osteoporosis found also a beneficial effect 
on blood pressure levels. In a study of 122 men 
receiving treatment with parenteral testosterone 
undecanoate over 15 month period, both systolic and 
diastolic blood pressure decreased significantly [31, 
30]. The maximum effect was achieved after nine 
months of testosterone administration. 
 
Figure 7: Descriptive characteristics: Systolic and diastolic blood 
pressure before treatment and after treatment in both groups. 
 
Furthermore, leptin also may have some role 
in achieving positive results in treatment group. Leptin 
is an adipose tissue hormone with so called “double 
action”: it affects receptors on Leydig cells, lowering 
testicular testosterone secretion. In addition, leptin 
suppresses pituitary LH secretion. As it was shown 
hypogonadal diabetic men have increased leptin 
levels. Further evidence for the association between 
hypogonadism and insulin levels in men has been 
reported in studies on patients undergoing treatment 
for prostate carcinoma where androgen ablation is the 
main treatment [33]. In our study testosterone 
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replacement therapy reduced leptin levels in addition 
to the independent effects of weight loss in lowering 
leptin levels. A limitation of this study is the relatively 
small samples of subjects involved that can limit the 
generalizability of the study. 
In conclusion, our study demonstrated that it 
is possible to regulate blood pressure, lipid profile, 
HbA1c, weight - by raising testosterone levels in 
diabetic men with androgen deficiency [34]. In addition 
to traditional CV risk factors, novel risk factors are 
also inversely related to testosterone levels. Re-
instituting physiological levels of testosterone in 
hypoandrogenic men as our small study showed have 
an important role in reducing the prevalence of 
diabetic complication, but large-scale randomized 
placebo-controlled trials are needed. 
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